Clementia Pharmaceuticals IPO

8/3/2017

IPO

$120,000,000

We anticipate that we will use the net proceeds of this offering, together with our existing cash on hand, as follows: Approximately $65.0 million to fund expenses incurred in pursuing the registration of palovarotene in FOP, including conducting the Phase 3 MOVE clinical trial and additional clinical trials of palovarotene for the treatment of FOP; Approximately $25.0 million to fund expenses incurred in conducting the Phase 2/3 clinical trial of palovarotene for the treatment of MO; Approximately $10.0 million to fund expenses incurred in conducting the Phase 1 and Phase 2 clinical trials of palovarotene for the treatment of dry eye disease; and The remainder for working capital, general and administrative expenses, pre-commercial activities, research and development expenses, and other general corporate purposes.

Acquired or Merged

Biopharmaceutical

4150 Ste-Catherine St. West 550
Montreal QC, H3Z 2Y5
Canada

Not Recorded

Clementia Pharmaceuticals is focused on developing palovarotene for fibrodysplasia ossificans progressiva (FOP) and other diseases.